Glucose metabolic reprogramming in systemic lupus erythematosus and lupus nephritis: theoretical foundations and therapeutic implications
Frontiers in Immunology · 02.04.2026 · 17
DOI: 10.3389/fimmu.2026.1799232 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Immunology, online erschienen am 02.04.2026. Verfasst von Hongyong Su und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, National Clinical Key Specialty Construction Program (2023), Institute of Nephrology, Guangdong Provincial Key Laboratory o…. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Glucose, Lupus Nephritis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 150 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Lupus nephritis (LN) represents the most severe and frequent complication of systemic lupus erythematosus (SLE), yet its treatment remains a significant unmet clinical need. Recent advances in immunometabolism have revealed that glucose metabolic reprogramming—including shifts in glycolysis, the pentose phosphate pathway (PPP), and the tricarboxylic acid (TCA) cycle—plays a central role in driving pathogenic immune cell activation in SLE. However, a critical gap persists in understanding how these metabolic alterations specifically operate within the renal microenvironment to promote immune cell infiltration and intrinsic kidney cell injury in LN. This review synthesizes current evidence on the molecular mechanisms linking glucose metabolism to immune dysfunction in innate immune cells including monocytes/macrophages, neutrophils and DCs and adaptive immune cells including T cells, B cells and renal resident cells. We further discuss therapeutic strategies targeting metabolic pathways, including repurposed drugs (metformin, hydroxychloroquine, rapamycin), preclinical small molecules (PKM2, PFKFB3, LDHA, GLUT1 inhibitors), and combination therapies with biologics. Safety considerations, particularly the sensitivity of regulatory T cells (Tregs) to glycolysis inhibition, underscore the need for dose optimization. Finally, we highlight future directions, including real-time metabolic imaging, personalized glycolysis scoring, and spatiotemporal metabolic epigenetic models, which hold promise for advancing precision medicine in LN.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, National Clinical Key Specialty Construction Program (2023), Institute of Nephrology, Guangdong Provincial Key Laboratory of Autophagy and Major Chronic Noncommunicable Diseases, Key Laboratory…
- Faculty of Chinese Medicine, State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Macao, Macao SAR, China.
- Guangdong Medical University, Zhanjiang, China.
Zitieren
APA
Su, H., Zhang, L., Zhang, Q., Liu, L., Zhai, L., Chen, X., Yang, C., An, N., & Liu, H. F. (2026). Glucose metabolic reprogramming in systemic lupus erythematosus and lupus nephritis: theoretical foundations and therapeutic implications. Frontiers in Immunology, 17. https://doi.org/10.3389/fimmu.2026.1799232
Vancouver
Su H, Zhang L, Zhang Q, Liu L, Zhai L, Chen X, et al. Glucose metabolic reprogramming in systemic lupus erythematosus and lupus nephritis: theoretical foundations and therapeutic implications. Frontiers in Immunology. 2026;17. doi:10.3389/fimmu.2026.1799232
BibTeX
@article{Su2026,
author = {Su, Hongyong and Zhang, Le and Zhang, Qiaofei and Liu, Lijing and Zhai, Liping and Chen, Xiaocui and Yang, Chen and An, Ning and Liu, Hua-Feng},
title = {Glucose metabolic reprogramming in systemic lupus erythematosus and lupus nephritis: theoretical foundations and therapeutic implications},
journal = {Frontiers in Immunology},
year = {2026},
volume = {17},
doi = {10.3389/fimmu.2026.1799232}
}
EUVIMED